ArticleInfection and drug resistance2025
Clinical and Microbiological Characteristics of Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synergistic antimicrobial and antibiofilm effects of mycosynthesized MnO-MgO bimetallic nanoparticles against drug-resistant pathogens.BMC microbiology · 2026Article
- Clinical Distribution Characteristics and Antimicrobial Resistance Trends ofInfection and drug resistance · 2026Article
- Genomic characterization ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: We analyzed a cohort of patients with rUTIs caused by Results: A total of 41 patients with rUTIs were included, with 56.1% caused by CRKP. 97.01% of CRKP carry the Conclusion: This study demonstrates that patients with rUTIs caused by CRKP present significant complexity in terms of clinical features, strain resistance and virulence properties. When managing UTIs caused by CRKP, special care needs to be taken to manage recurrent infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.